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Transgenic mice that overexpress angiotensinogen, the
sole precursor of angiotensins, in their renal proximal tubular
cells develop hypertension, albuminuria, and tubular
apoptosis. These pathological changes are due to enhanced
generation of reactive oxygen species in the proximal tubule
cells. Here, we determined whether overexpression of
catalase to decrease oxidant injury in the proximal tubular
cells could reverse these abnormalities. Double-transgenic
mice specifically overexpressing angiotensinogen and
catalase in their renal proximal tubular cells were created
by cross-breeding the single transgenics. Non-transgenic
littermates served as controls. Overexpression of catalase
prevented hypertension, albuminuria, tubulointerstitial
fibrosis, and tubular apoptosis in the angiotensinogen
transgenic mice. Furthermore, the double transgenics had
lower reactive oxygen species generation and reduced pro-
fibrotic and apoptotic gene expression in the renal proximal
tubular cells. Renal angiotensin converting enzyme-2
expression and urinary angiotensin 1–7 levels were
downregulated in the single but normal in the
double-transgenic mice. Thus, we suggest that the intrarenal
renin-angiotensin system and reactive oxygen species
generation have an important role in the development of
hypertension and renal injury.
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Angiotensin II (Ang II) has key roles in hypertension and
renal injury leading to end-stage renal disease. Chronic
treatment with renin-angiotensin system (RAS) blockers
(angiotensin-converting enzyme inhibitors and/or antago-
nists of angiotensin II (subtype-1) receptor (AT1-R)) lowers
blood pressure and delays nephropathy progression.1–4
The degree of glomerulosclerosis, tubulointerstitial fibro-
sis, and tubular atrophy, determines the rate of decline in
renal function.5 Ang II is involved in these processes and its
action is largely mediated through the AT1-R that is present
throughout the kidney.6 The AT1-R is expressed on both the
luminal and basolateral membranes of renal proximal tubular
cells (RPTCs). It has been postulated that Ang II produced
within the renal proximal tubule (RPT) may be more
important than Ang II derived from circulation in inducing
kidney damage. Indeed, luminal and tissue Ang II levels are
far higher than those in plasma.7–9 Intrarenal levels of
angiotensinogen (Agt) and Ang II are elevated in hyper-
tension and diabetes,10–15 contributing not only to hyper-
tension but also to kidney injury.
The existence of a local intrarenal RAS is now well
accepted and all components of the RAS are expressed in
RPTCs.16–22 Transgenic mice (Tgs) overexpressing rat Agt
in their RPTCs are prone to developing hypertension,
albuminuria, and renal injury and treatment with RAS
blockers normalizes these parameters.23,24 Overexpression
of Agt increases reactive oxygen species (ROS) production
in RPTCs through NADPH oxidase activation, and treatment
of Agt-Tgs with apocynin (an inhibitor of NADPH oxidase)
attenuates ROS generation and renal injury but not hyper-
tension.25 Thus, it is unclear whether ROS mediate intrarenal
RAS actions on both hypertension development and kidney
injury.
The present in vivo study sought to determine whether
a mouse model characterized by rat catalase (Cat) over-
expression in RPTCs could prevent ROS generation and
the development of hypertension, thereby improving the pro-
fibrotic and pro-apoptotic effects engendered by upregulated
intrarenal RAS.
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RESULTS
Tissue-specific expression of rat Agt (rAgt) and rat Cat (rCat)
transgenes in Tgs
The rAgt-HA (a sequence encoding amino acid residues
98–106 (YPYDVPDYA) of human influenza virus hemagglu-
tinin-tag) and rCat-HA transgenes were highly expressed in
RPTs of adult male Tgs (Figure 1a) but not in other tissues
(liver, spleen, lung, heart, brain and testis; data not shown).
Non-Tgs (wild type) did not express transgenes. Immuno-
staining confirmed the increased expression of Agt
(Figure 1b, B and D) and Cat proteins (Figure 1c, C and
D) in RPTCs of Tgs as compared with non-Tg littermates.
Renal morphology, albuminuria, hypertension and heart
weight in Tgs
Although kidney/body weight ratios were similar among all
groups (Figure 2a), renal damage was evident only in Agt-Tgs
(Figure 2b, B) as compared with non-Tgs (Figure 2b, A) and
Cat-Tgs (Figure 2b, C). Histological findings included loss of
brush border in RPTCs and some RPTCs were flattened or
atrophied in Agt-Tg kidneys, consistent with RPTC damage.
Overexpressing of Cat markedly attenuated these abnormal-
ities (Figure 2b, D). RPTC volume was significantly higher
in Agt-Tgs than in non-Tgs and Cat-Tgs (Figure 2c).
Overexpression of Cat effectively attenuated this change in
Agt/Cat-Tgs. In contrast, glomerular volume did not differ
significantly between Tgs and non-Tgs, and was unaffected by
Cat overexpression (Figure 2d).
Consistent with previous studies (23, 24), an increased
urinary albumin/creatinine ratio (ACR) (Figure 3a) was
evident in Agt-Tgs at 20 weeks old as compared with non-
Tgs and Cat-Tgs. Cat overexpression normalized ACR in Agt/
Cat-Tgs. SBP was significantly higher after 12 weeks in male
Agt-Tgs as compared with non-Tgs and Cat-Tgs (Po0.05,
increased by 10 to 15 mm Hg) and remained so (Figure 3b).
Overexpression of Cat normalized SBP in Agt/Cat-Tgs
(Figures 3b and c). Wet heart weight/body weight ratios did
not differ significantly among different groups (Figure 3d).
Oxidative stress in Tg kidneys
ROS generation and NADPH oxidase activity were signifi-
cantly higher in RPTs of Agt-Tgs than in non-Tgs (Figures 4a
and b, respectively). Overexpression of Cat effectively
inhibited ROS generation and NADPH oxidase activity in
RPTs of Cat-Tgs and Agt/Cat-Tgs. Similarly, HO-1 expression
(an oxidative stress-induced gene) increased in RPTCs of Agt-
Tgs (Figure 4c, B) as compared with non-Tgs (Figure 4c, A)
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Figure 1 | Transgene expression. (a) RT-PCR product showing
expression of rAgt-HA and rCat-HA mRNA in renal proximal
tubules of adult male non-Tg and Tg mice (20 weeks old).
rAgt-HA, rCat-HA, and b-actin fragments are indicated. (b)
Immunohistochemical staining ( 600 magnification) of Agt in
kidneys of male non-Tg (A), Agt-Tg (B), Cat-Tg (C), and Agt/Cat-Tg
(D) mice by employing rabbit anti-rAgt (Rabbit no. 16, 1:100
dilution) polyclonal antibody. Immunostaining of Agt ( 200
magnification) of kidneys is shown in Supplemental Figure B. (c)
Immunohistochemical staining ( 600 magnification) of Cat in
kidneys of male non-Tg (A), Agt-Tg (B), Cat-Tg (C), and Agt/Cat-Tg
(D) mice by employing rabbit anti-bCat (1:100 dilution) polyclonal
antibody. Non-immune normal rabbit serum displayed no
immunostaining in Tg mouse kidneys (not shown). Agt,
angiotensinogen; Cat, cat catalase; Tg, transgenic.
Kidney International (2010) 77, 1086–1097 1087
N Godin et al.: Catalase and hypertension in transgenic mice o r ig ina l a r t i c l e
and Cat-Tgs (Figure 4c, C). Cat overexpression attenuated
HO-1 expression in RPTCs of Agt/Cat Tgs (Figure 4c, D).
Cat overexpression on ACE and ACE2 expression in Tgs
There was intense immunostaining for ACE (Figure 5a, A) in
RPTCs of non-Tgs. Decreased ACE immunostaining was
observed in RPTCs of Agt/Cat-Tg (Figure 5a, D) as compared
with non-Tg (Figure 5a, A), Agt-Tg (Figure 5a, B), and
Cat-Tg (Figure 5a, C). In contrast, decreased immunostaining
for ACE2 (Figure 5b, B) was observed in RPTCs of Agt-Tgs as
compared with non-Tgs (Figure 5b, A) and Cat-Tgs (Figure
5b, C). Overexpression of Cat-normalized ACE2 immuno-
staining in RPTCs of Agt/Cat-Tgs (Figure 5b, D) as compared
with non-Tgs. Western blotting and RT-qPCR for protein
and mRNA expression of ACE (Figure 5c and e) and ACE2
(Figure 5d and f) from isolated RPTs confirmed these findings.
Ag-Tg mice showed increased urinary Ang II levels and
decreased Ang 1-7 levels compared with non-Tg and Cat-Tg
mice, and these changes were normalized in Agt/Cat-Tg mice
(Figure 6a and b). Furthermore, ACE activity in RPT was
significantly higher in Agt-Tg mice than in non-Tgs, Cat-Tgs,
and Agt/Cat-Tgs (Figure 6c).
Tubulointerstitial fibrosis
Agt-Tg kidneys showed enhanced expression of collagenous
components of extracellular matrix proteins (Figure 7a, B),
immunoreactive collagen type IV (Figure 7b, B), and mono-
cyte chemotactic protein-1 (MCP-1) (Figure 7c, B) as
compared with the kidneys of non-Tg (Figure 7a, A; b, A;
and c, A) and Cat-Tgs (Figure 7a, C; b, C; and c, C). Cat over-
expression in Agt/Cat-Tgs attenuated these changes (Figure
7a, D; b, D; and c, D). Quantification on sections stained
with Masson’s trichrome (Figure 7d) and RT-qPCR for
collagen type IV (Figure 7e) and MCP-1 (Figure 7f) mRNA
expression confirmed the findings.
Agt-Tg kidneys also showed higher expression of trans-
forming growth factor-b 1 (TGF-b1) (Figures 8a, B) and
plasminogen activator inhibitor-1 (PAI-1) (Figure 8b, B)
than non-Tg kidneys (Figures 8a, A and b, A) and Cat-Tg
kidneys (Figures 8a, C and b, C). Overexpression of Cat in
RPTCs of Agt/Cat-Tgs prevented the increase in TGF-b1 and
PAI-1 expression (Figures 8a, D and b, D). Quantification of
TGF-b1 and PAI-1 protein by western blotting (Figures 8c
and d, respectively) and mRNA by RT-qPCR (Figure 8e and f,
respectively) further validated these data.
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Figure 2 |Kidney to body weight ratio and morphological analysis in male non-Tg and Tg mouse kidneys at week 20.
(a) Kidney-to-body weight ratio. The kidney-to-body weight ratio was measured as the weight of two kidneys per body weight.
All data are expressed as the mean±s.d., N¼ 8 (***Po0.005; NS not significant). (b) Hematoxylin/eosin (H/E) staining ( 600 magnification)
of kidneys of male (A) non-Tgs, (B) Agt-Tgs, (C) Cat-Tgs, and (D) Agt/Cat-Tgs. Arrows indicate tubular damage, that is, RPTCs without brush
border or cellular atrophy. H/E staining ( 200 magnification) of kidneys is shown in Supplemental Figure A. (c) Mean RPTC volume of male
non-Tg and Tg mouse kidneys at week 20. (d) Mean glomerular volume of male non-Tg and Tg mouse kidneys at week 20.
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Cat overexpression prevents RPTC apoptosis in Tgs
The number of apoptotic RPTCs was higher in Agt-Tgs
(Figure 9a, B) than in non-Tgs (Figure 9a, A) and Cat-Tgs
(Figure 9a, C). Overexpression of Cat effectively attenuated
RPTC apoptosis in Agt/Cat-Tgs (Figure 9a, D). Semi-quanti-
tative estimation of the number of apoptotic RPTCs
confirmed these findings (Figure 9c).
Immunohistochemistry showed increased staining for
active caspase-3 (Figure 9b, B) in RPTCs of Agt-Tgs as
compared with non-Tgs (Figure 9b, A) and Cat-Tgs (Figure
9b, C). Overexpression of Cat effectively attenuated increases
in caspase-3 in RPTCs of Agt/Cat-Tgs (Figure 9b, D). Similar
trends were detected by caspase-3 activity assay from isolated
RPTs (Figures 9d).
An increased Bax/Bcl-xL ratio expression is associated
with promotion of apoptosis. We next investigated whether
this also occurred in RPTs of our Tg mice. Bax mRNA
(Figure 9e) expression was augmented in RPTs of Agt-Tgs
as compared with non-Tg littermates and Cat-Tgs. In
contrast, Bcl-xL mRNA (Figure 9f) expression was signi-
ficantly lower in RPTs of Agt-Tgs than in non-Tgs and
Cat-Tgs. Cat overexpression reversed these changes in RPTs
of Agt/Cat-Tgs.
DISCUSSION
This study shows that Cat overexpression in RPTCs
effectively prevents hypertension, albuminuria, tubulointer-
stitial fibrosis, and RPTC apoptosis as well as normalizes
RPTC ACE2 expression and urinary Ang 1–7 levels in Agt/
Cat-Tgs as compared with Agt-Tgs. These findings indicate
that intrarenal RAS-induced ROS generation and down-
regulation of ACE2 expression likely have an important role
in the development of hypertension, tubulointerstitial
fibrosis, and RPTC apoptosis.
In the kidney, Cat is localized predominantly in the
cytoplasm of proximal tubules of the superficial cortex.
Cat was not detected in the glomeruli, distal tubules, loop of
Henle, and collecting ducts.26 Cat overexpression renders cell
more resistant to H2O2 toxicity and oxidant-mediated injury.
Transgenic mice overexpressing Cat are protected against
myocardial injury in hypertension.27 However, little is known
about whether overexpression of Cat in the kidney could
protect against kidney injury.
Consistent with our previous findings,25 kidney/body
weight ratios and glomerular volume did not differ signi-
ficantly in non-Tgs and Tgs, whereas RPTC volume was
significantly higher in Agt-Tgs than non-Tgs and was
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Figure 3 |Urinary albumin/creatinine ratio (ACR) and systolic blood pressure (SBP) in male non-Tg and Tg mice. (a) Urinary albumin
(mg/ml)/creatinine (mg/dl) ratio. (b) Longitudinal changes in mean SBP in male non-Tg (B), Agt-Tg (’), Cat-Tg (D), and Agt/Cat-Tg (&)
mice from week 10 to week 20 for a 10-week period. Baseline SBP was measured in all mice for 5 days before the first SBP reading. (c) Cross-
sectional analysis of SBP (measured 2 to 3 times per week in the morning without fasting, week 20) in non-Tg and Tg mice. (d) Heart-
to-body weight ratio. The heart-to-body weight ratio was measured as the wet weight of heart without blood per body weight. All data
are expressed as means±s.d., N¼ 8 (*Po0.05; **Po0.01; ***Po0.005; NS not significant).
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normalized in Agt/Cat-Tgs. These observations indicate that
Agt overexpression and RAS activation stimulate RPTC
hypertrophy without affecting glomerular tuft volume.
However, whether intrarenal RAS activation would affect
glomerular function such as glomerular filtration rate
remains to be determined.
Albuminuria (measured by albumin/creatinine ratio,
ACR) was detectable after week 16–20 in Agt-Tgs but not
in non-Tgs. Cat overexpression in Agt/Cat-Tgs significantly
reduced albuminuria at week 20 compared with Agt-Tgs.
These observations imply a link between intrarenal RAS
activation, ROS, and albuminuria independently of SBP.
Indeed, this possibility is supported by our earlier report
in which hydralazine (a vasodilator) lowered SBP but not
albuminuria in Agt-Tgs.25
Consistent with previous studies,23–25 baseline SBP was
significantly higher in Agt-Tgs than in non-Tgs. Cat over-
expression in RPTCs of Agt/Cat-Tgs effectively normalized
SBP. Interestingly, significantly higher urinary Ang II and
lower Ang 1–7 levels were found in Agt-Tgs than in non-Tgs
and these changes were normalized in Agt/Cat-Tg mice.
Similar trends were detected in ACE activity in RPT. These
findings strongly suggest that Ang II increases ACE activity
via ROS generation and point toward an important role
for the augmented intrarenal Ang II/Ang 1–7 ratio in the
development of hypertension.
It is not known how Cat overexpression normalizes
hypertension in Agt/Cat-Tgs. The hypothesis that Ang II may
downregulate ACE2 gene expression, and subsequently favor
hypertension development has received considerable atten-
tion. Indeed, Ferrario et al.28 report that RAS blockade
increases kidney cortex ACE2 activity and urinary Ang 1–7
excretion in normotensive Lewis rats. Recent studies by Koka
et al.29 established that ACE and ACE2 levels are low and
high, respectively, in normal human kidneys whereas ACE
and ACE2 expression is reversed in human hypertensive
kidneys. Furthermore, they showed that Ang II upregulated
ACE and downregulated ACE2 expression via AT1R coupled
to extracellular signaling-regulated kinase 1 and 2 (ERK ½)
and p38 mitogen-activated protein kinase (p38 MAPK)
signaling in vitro.29 Thus, our findings support the concept
that RAS activation induces ROS generation via enhanced
NADPH oxidase activity, upregulates ACE activity and
downregulates ACE2 expression. Cat overexpression reverses
these effects and thereby prevents hypertension development.
The underlying mechanisms of ROS upregulation of ACE
activity have yet to be defined.
Our data indicate that intrarenal Agt gene expression and
ROS generation are important in mediating tubulointerstitial
fibrosis and tubular apoptosis. Consistent with previous
studies,24,25 expression of extracellular matrix proteins such
as collagen type IV and pro-fibrotic gene such as TGF-b1 were
enhanced in the tubulointerstitium; furthermore, PAI-1
expression in RPTCs of Agt-Tgs was increased. In contrast,
the expression of these genes was normalized in Agt/Cat-Tgs.
Our findings on increased expression of MCP-1 in Agt-Tg
kidneys as compared with non-Tgs but normalized in Agt/
Cat-Tgs further supported the important role of intrarenal
RAS and ROS in the development of tubulointerstitial fibrosis.
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Figure 4 |ROS generation, NADPH oxidase activity and
immunostaining of HO-1 in RPTs of non-Tg and Tg mice.
(a) ROS generation. (b) NADPH oxidase activity. The actual NADPH
oxidase activity of the controls (non-Tg) was 376.6±86.6 RLU/
min/mg protein. All data are expressed as means±s.d., N¼ 8
(*Po0.05; **Po0.01; ***Po0.005). (c) Immunostaining of HO-1.
(A) Non-Tg control littermate; (B) Agt-Tg mouse; (C) Cat-Tg mouse;
(D) Agt/Cat-Tg mouse. Magnification  600. Arrow indicates
representative HO-1 immuno-positive cells in the kidney. RLU,
relative light units; ROS, reactive oxygen species.
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The numbers of TUNEL-positive RPTCs were significantly
higher in Agt-Tg than in non-Tgs, which is consistent
with previous reports that Ang II induces RPTC apoptosis
in vivo.24,25,30,31 Consistent with the TUNEL assay, Agt-Tgs
showed enhanced active caspase-3 expression and activity
in their kidneys. These changes were attenuated by over-
expression of Cat in concomitant upregulation of Bax
mRNA and downregulation of Bcl-xL mRNA expression.
Cat overexpression reversed the Bax/Bcl-xL mRNA ratio. An
increased Bax/Bcl-xL ratio is consistent with promotion of
apoptosis, a mechanism by which RAS and ROS enhance
tubular apoptosis in Agt-Tgs.
Based on our observations, we can offer two hypotheses
concerning the ways in which intrarenal Ang II induces
hypertension and kidney injury. First, intrarenal Ang II might
affect SBP via enhanced renal Naþ absorption through
direct stimulation of the sodium–potassium adenosine
triphosphatase (Naþ–Kþ–ATPase) and sodium/hydrogen
exchanger-3 (NHE-3) activity in RPTs.32,33 Second, because
Ang II induces ROS generation and upregulates AT1R
expression, it would secondarily enhance renal sodium
absorption via Naþ–Kþ–ATPase activation. For example,
Silva and Soares-da-Silva34 reported that ROS upregulate
Naþ–Kþ–ATPase activity and gene expression in opossum
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Figure 5 |ACE and ACE2 expression in male non-Tg and Tg mouse kidneys at week 20. (a) Immunostaining for ACE: (A) non-Tg control
littermate; (B) Agt-Tg mouse; (C) Cat-Tg mouse; (D) Agt/Cat-Tg mouse. Magnification  600. Arrows indicate ACE immuno-positive cells.
(b) Immunostaining for ACE2: (A) non-Tg control littermate; (B) Agt-Tg mouse; (C) Cat-Tg mouse; (D) Agt/Cat-Tg mouse. Magnification
 600. Arrows indicate ACE2 immuno-positive cells. Western blotting of ACE (c) and ACE2 (d) in mouse RPTs. The same membrane was
re-blotted for b-Actin. RT-qPCR of ACE (e) and ACE2 (f) in mouse RPTs. ACE, ACE2 and b-actin mRNAs were run simultaneously in the
same RT-qPCR assay. ACE and ACE2 mRNA levels were normalized by corresponding b-actin mRNA levels. mRNA levels in non-Tg were
considered as 100%. All data are expressed as means±s.d., N¼ 8 (*Po0.05; NS, non-significant).
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RPTCs. More recently, Banday et al.35 reported that oxidative
stress-mediated AT1R upregulation causes loss of the Na
þ–
Kþ–ATPase biphasic response and enhances Naþ–Kþ–
ATPase activity in Sprague–Dawley rats. This possibility is
supported by our preliminary (unpublished) results that
urinary sodium levels were significantly lower in Agt-Tgs
than in non-Tgs and were normalized in Agt/Cat-Tgs.
Despite the fact that we previously reported that apocynin,
an inhibitor of NADPH oxidase, was ineffective in preventing
hypertension in Agt-Tgs,25 our present study found that
overexpression of Cat in RPTCs completely normalized SBP
in Agt/Cat-Tgs. A possible explanation for these apparently
inconsistent results is that renal Ang II may affect SBP
through direct vasoconstriction of glomerular arterioles
through the Ang II AT1-receptor independently of ROS
generation. Apocynin is a weak inhibitor of vascular NADPH
oxidase in the absence of myeloperoxidase, which converts
apocynin into active apocynin dimer.36 Our current findings
suggest that Cat-overexpression likely alleviates oxidative
stress regardless of its source, whereas apocynin could only
influence NADPH oxidase-dependent ROS production.
Thus, Cat overexpression appears to be more effective than
apocynin because NADPH oxidase is not the sole source of
ROS in RPTCs of Agt-Tg mice.
Recent studies have shown that chronic hypoxia may be a
mechanism of progression of chronic kidney diseases and
that the activation of the RAS is intimately involved in
chronic hypoxia of the kidney (see recent reviews: Fine and
Norman;37 Nangaku and Fujita38). Thus, it is possible that
the augmented renal RAS activation in our Agt-Tg mice
might induce renal hypoxia via both hemodynamic and non-
hemodynamic mechanisms, as postulated by Nangaku and
Fujita.38 The beneficial effects of Cat overexpression are, at
least in part, mediated by the amelioration of local hypoxia
via degrading hydrogen peroxide to oxygen and water in
RPTCs. However, whether activation of the intrarenal RAS
may directly affect RPTC hypoxia remains to be deter-
mined. Finally, since chronic hypoxia in the kidney is an
ideal therapeutic target and Cat expression might alleviate
cellular hypoxia, our findings suggest that the activation of
Cat expression in RPTCs by novel drugs may offer novel
therapeutics for retarding or preventing chronic kidney disease.
In summary, our study indicates an important role for
intrarenal RAS and ROS in hypertension, albuminuria,
interstitial fibrosis and RPTC apoptosis observed in Agt-
Tgs. The Agt/Cat-Tg model may be useful for studying
the mechanism (s) of Ang II action on ROS generation
and kidney-dependent hypertension. Our data suggest that
selective inactivation of renal ROS generation and upregula-
tion of ACE2 and Cat may provide novel therapeutic targets
for preventing hypertension and reversing nephropathy in
hypertension and renal disease.
MATERIALS AND METHODS
The pKAP2 plasmid contains the kidney androgen-regulated
promoter (KAP), which is responsive to testosterone stimulation,
was obtained from Dr Curt D Sigmund (University of Iowa, Iowa,
IA, USA) and has been described elsewhere.39,40 rCat cDNA was a
gift from Dr Paul E Epstein (University of Louisville, Louisville, KY,
USA). Rabbit polyclonal antibodies anti-heme oxygenase-1 (HO-1),
anti-bovine Cat and monoclonal antibodies against b-actin were
purchased from Assay Designs (Ann Arbor, MI, USA) and Sigma-
Aldrich Canada (Oakville, ON, Canada), respectively. Polyclonal
anti-ACE and anti-PAI-1 antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) whereas anti-ACE2 and
anti-MCP-1 were procured from R & D Systems. (Minneapolis, MN,
USA). Polyclonal anti-cleaved caspase-3 antibody and monoclonal
anti-collagen type IV antibody were obtained from New England
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Figure 6 |Urinary Ang II and Ang 1–7 levels, and renal ACE
activity in male non-Tg and Tg mouse kidneys at week 20.
Cross-sectional analysis of urinary Ang II (a), Ang 1-7 (b) levels,
and RPT ACE activity (c) in non-Tg and Tg mouse kidneys at week
20. Mouse urines were extracted and assayed by Peptide Enzyme
Immunoassay (ELISA) according to the protocol provided by the
manufacturer (Bachem Americas, CA, USA). The actual ACE activity
of non-Tgs is 419±134 RLU/min/mg protein. Values are expressed
as means±s.d., N¼ 8 in males (*Po0.05).
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Biolabs (Pickering, ON, Canada) and Chemicon International
(Temecula, CA, USA), respectively. Rabbit anti-rat Agt antibodies
were generated in our laboratory (JSDC).21 These antibodies are
specific for intact rat and mouse Agt (that is, 55–62 kDa Agt) and do
not cross-react with pituitary hormone preparations or other rat or
mouse plasma proteins.21 Oligonucleotides were procured from
Invitrogen (Burlington, ON, Canada). Restriction and modifying
enzymes were purchased from either Invitrogen or La Roche
Biochemicals (Laval, QC, Canada).
Generation of KAP2-Agt/Cat-Tgs
The creation of Tgs overexpressing rAgt or rCat in their RPTCs has
been described previously.14,23 Briefly, cDNA encoding full-length
rAgt or rCAT fused with HA and terminating codon at the 30 end
(NotI site flanked at both 50- and 30-terminali) were inserted into
pKAP2 plasmid at the NotI site of exon II of human Agt gene. The
isolated KAP2-rAgt or KAP2-rCAT transgene was then micro-
injected into 1-cell fertilized mouse embryos using a standard
procedure. The positive Tg founders were then crossed with wild
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Figure 7 |Masson’s trichrome staining, collagen type IV and MCP-1 expression in male non-Tg and Tg mouse kidneys at week 20.
Masson’s trichrome staining (a), collagen type IV (b) and MCP-1 (c) immunostaining of male non-Tg and Tg mouse kidneys at week 20.
(a), (b), and (c): (A) non-Tg control littermate; (B) Agt-Tg mouse; (C) Cat-Tg mouse; (D) Agt/Cat-Tg mouse. Arrows indicate locations of
collagenous materials (a), collagen type IV (b) and MCP-1 (c) immunostaining. Magnification  600. Quantification of collagenous
component accumulation (Masson’s trichrome staining) (d), RT-qPCR of collagen type IV, and (e) MCP-1 (f) mRNA. Collagen type IV, MCP-1
and b-actin mRNAs were run simultaneously in the same RT-qPCR assay. Collagen type IV and MCP-1 mRNA levels were normalized
by corresponding b-actin mRNA levels. mRNA levels in non-Tg were considered as 100%. All data are expressed as means±s.d., N¼ 8
(*Po0.05; ***Po0.005). MCP-1, monocyte chemotactic protein-1.
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type C57Bl6 mice for F1 generation. Breeding was continued until
homozygous F3 and F4 Tg mice were obtained. Agt/Cat Tgs were
created by cross-breeding the Agt-Tgs (no. 388) with Cat-Tgs (no.
688) (C57Bl6 background) and by continuing breeding until
homozygous Agt/Cat-Tgs were obtained.
Physiological studies
Unless otherwise noted, we used male Tgs aged 10–20 weeks at data
collection. Non-Tg littermates served as controls. All animals
received standard mouse chow and water ad libitum. Animal care
and procedures were approved by the CRCHUM’s Animal Care
Committee.
Systolic blood pressure (SBP) was monitored with a blood
pressure-2000 tail-cuff pressure machine (Visitech Systems, Apex,
NC, USA)15,23–25 in the morning, at least 2–3 times a week, for 10
weeks. The mice were trained in the procedure for at least 15–20 min
per day for 5 days before the first SBP measurements. SBP values
represent the mean±s.d. of 2–3 determinations per week per animal
per group (N¼ 8 animals per group). All animals were euthanized at
age 20 weeks. Twenty-four hours before euthanasia, they were
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Figure 8 | TGF-b1 and PAI-1 expression in male non-Tg and Tg mouse kidneys at week 20. TGF-b1 (a) and PAI-1 (b) immunostaining
of male non-Tg and Tg mouse kidneys at week 20. (a) and (b): (A) non-Tg control littermate; (B) Agt-Tg mouse; (C) Cat-Tg mouse;
(D) Agt/Cat-Tg mouse. Arrows indicate TGF-b1 immuno-positive areas (a) or PAI-1 immuno-positive cells (b). Magnification  600. Western
blotting of TGF-b1 (c) and PAI-1 (d) expression in mouse RPTs. RT-qPCR of TGF-b1 (e) and PAI-1 (f) mRNA. TGF-b1, PAI-1 and b-actin mRNAs
were run simultaneously in the same RT-qPCR assay. TGF-b1 and PAI-1 mRNA levels were normalized by corresponding b-actin mRNA levels.
mRNA levels in non-Tg were considered as 100%. All data are expressed as means±s.d., N¼ 8 (*Po0.05; ***Po0.005). PAI-1, plasminogen
activator inhibitor-1.
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housed individually in metabolic cages. Body weight was recorded.
Urine was collected and assayed for albumin and creatinine (ELISA,
Albuwell and Creatinine Companion, Exocell, Philadelphia, PA,
USA).23–25 Both kidneys and hearts were removed immediately after
euthanasia. The decapsulated kidneys and wet hearts were weighed.
The left kidneys were processed for histology and apoptosis study,
and the right kidneys were used for isolation of renal proximal
tubules (RPTs) by Percoll gradient.23–25
Histological studies
Kidney sections (4–5 sections, 3–4 mm thick, per kidney) from eight
animals per group were stained with hematoxylin and eosin or
Masson’s trichrome stain and analyzed visually under a light
microscope by two investigators blinded to the treatments.23–25
Masson’s trichrome-stained images were quantified by NIH ImageJ
software (http://rsb.info.nih.gov/ij/).
The mean glomerular volumes on 30 random glomerular sections
per mouse were determined by the method of Weibel41 with the
Motics Images Plus 2.0 image analysis software (Motic, Richmond,
BC, Canada). RPTC volume was measured from 100 RPTCs per
mouse with the same software. Outer cortical RPTs with similar
cross-sectional views and clear nuclear structure were selected. The
mean cell volume was estimated by the Nucleator method.42
Immunohistochemical staining was performed according to the
standard avidin–biotin–peroxidase complex method (ABC Staining
System, Santa Cruz Biotechnologies, Santa Cruz, CA, USA).23–25
Immunostaining with nonimmune normal rabbit serum (displayed
no immunostaining) for putative genes in both non-Tg and Tg
mouse kidneys served as controls (not shown). The percentage
of apoptotic RPTCs (TUNEL kit, Roche Diagnostics, Laval,
QC, Canada) was estimated semi-quantitatively as previously
described.24,25
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Figure 9 |Apoptosis in male non-Tg and Tg mouse kidneys. (a) TUNEL assay. (A) Non-Tg control; (B) Agt-Tg mouse; (C) Cat-Tg mouse; (D)
Agt/Cat-Tg mouse. Magnification  600. (b) Immunostaining of active caspase-3 (anti-a-active caspase-3 antibodies (1: 50 dilution)).
(A) non-Tg control; (B) Agt-Tg mouse; (C) Cat-Tg mouse; (D) Agt/Cat-Tg mouse. Arrows indicate apoptotic cells in proximal tubules.
(c) Bar graph showing semi-quantitative analysis of apoptotic RPTCs from male non-Tg and Tg mouse kidneys. (d) Caspase-3 activity in
RPTs from male non-Tg and Tg mouse kidneys. RT-qPCR of Bax (e) and Bcl-xL (f) mRNA. Bax, Bcl-xL, and b-actin mRNAs were run
simultaneously in the same RT-qPCR assay. Bax and Bcl-xL mRNA levels were normalized by corresponding b-actin mRNA levels.
mRNA levels in non-Tg were considered as 100%. All data are expressed as means±s.d., N¼ 8 (*Po0.05; ***Po0.005).
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Urinary Ang II and Ang 1–7 measurement and ACE activity
assay
Mouse urine samples (180 ml per animal) were initially purified by
C18 Sep-Pak columns (Waters Corporation, MA USA) and then
extracted with an extraction kit (Bachem Americas, Torrance, CA
USA) according to the recommended number III protocol. The
residues were then resuspended in 120 ml of EIA buffer solution
(supplied by Bachem Americas) and aliquots (50 ml each) were used
for Ang II or Ang 1–7 measurement by respective specific ELISA
(Bachem Americas).
ACE activity was quantified by the cleavage of the substrate
hippuryl-L-histidyl-L-leucine (HHL, Sigma-Aldrich Canada) fol-
lowed by labeling with o-phthaldialdehyde (OPA, Sigma-Aldrich
Canada) according to the method described by Dean et al.43 with
slight modifications. Briefly,B40 mg of proteins (RPT extracts) were
diluted in sodium borate buffer (0.4 mol/l boric acid, 0.3 mol/l
NaCl, pH8.3) (final volume 50 ml) and incubated for 1 h at 371C in
the presence or absence of 100mmol/l perindopril (an ACE
inhibitor). The reaction was stopped by the addition of 0.34 mol/l
NaOH (final concentration 0.28 mol/l) followed by labeling with
40 ml of 20 mg/ml OPA. After incubation for 10 min, 100 ml of
3 mol/l HCl was added and the measurements of fluorescence were
carried at wavelengths of 360 nm excitation and 530 nm emission.
The values of ACE activity were calculated by substraction of
perindopril-containing tubes from those without perindopril. All
values were normalized by the protein concentrations and expressed
as the relative light unit emission per mg protein.
ROS generation, NADPH oxidase and caspase-3 activity
assays
ROS production in the kidney was assessed by ROS generation in
freshly isolated RPTs by the lucigenin method14,15,24,25,44 and
NADPH oxidase activity.25 Oxidative stress in RPTCs in vivo was
assessed by standard immunohistochemical staining for heme
oxygenase 1 (HO-1, an oxidative stress-inducible gene that confers
cellular oxidative stress in vivo).45
Briefly, RPTs were washed in modified Krebs buffer containing
NaCl (130 mmol/l), KCl (5 mmol/l), MgCl2 (1 mmol/l), CaCl2
(1.5 mmol/l), K2HPO4 (1 mmol/l) and Hepes (20 mmol/l), pH 7.4,
and resuspended in 900 ml of Krebs buffer supplemented with 1 mg/
ml bovine serum albumin (BSA). The cell suspension was
transferred to plastic tubes and ROS production was assessed in a
luminometer (LB 9507; Berthold, Wildbad, Germany). Measure-
ment began with an injection of 100 ml lucigenin (final concentra-
tion 5 104 M). Photon emissions were counted every 1 min for
up to 20 min. Peak emissions at 10 min were recorded from each
group for comparison. Modified Krebs buffer served as a control
(blank). Solutions containing lucigenin without RPTs did not
display any significant interference in the lucigenin assay. ROS
production in RPTs was normalized with protein concentration and
expressed as relative light units per min per mg protein.
NADPH oxidase activity was measured by a luminescence
assay.25,46,47 Briefly, RPTs were homogenized in lysis buffer and
assayed in 50 mmol/l phosphate buffer, pH. 7.0, containing 1 mmol/l
EGTA, 150 mmol/l sucrose, 5 mM lucigenin and 100mM NADPH
(final volume, 0.9 ml). The reaction was started after the addition of
100ml (B100mg) of homogenate protein. No activity was detected
in the absence of NADPH.
Caspase-3 activity was assayed on frozen (801C) RPTs with
caspase-3 assay kits (BD Bioscience Pharmingen, Mississauga, ON,
Canada), as described previously.24,25
Western blotting and real time-quantitative polymerase
chain reaction (RT-qPCR) assays for gene expression
Western blotting for ACE, ACE2, TGF-b1, and PAI-1 was performed
as described elsewhere using RPT lysates.14,15,24,25 The membrane
was then blotted with primary anti-ACE, ACE2, TGF-b1, or PAI-1
antibody and then re-blotted with anti-b-actin monoclonal antibodies
and chemiluminescent developing reagent (Roche Biochemicals). The
relative densities of ACE, ACE2, TGF-b1, PAI-1, and b-actin bands
were quantified by computerized laser densitometry (ImageQuant
software (version 5.1), Molecular Dynamics, Sunnyvale, CA, USA).
ACE, ACE2, collagen type IV, TGF-b1, PAI-1, MCP-1, Bax,
Bcl-xL, and b-actin mRNA expression in RPTs was quantified by
RT-qPCR with forward and reverse primers corresponding to the
respective genes (Table 1) according to the methods as described
previously.14,15,24,25
Statistical analysis
Data are expressed as mean±s.d. The data are analyzed by one-way
ANOVA and the Bonferroni test. P-values o0.05 were considered
significant.
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Table 1 | Primers for genotyping and RT-qPCR
Primers for genotyping:
Agt (S) N+676 to N+695 (50-CCTCGCTCTCTGGACTTATC-30) (BC087679)
Cat (S) N+1152 to N+1170 (50-CACTCACCGCCACCGCCTG-30) (BC081853)
HA (AS) (50-GGCGTAGTCAGGCACGTCGT-30)
Primers for RT-qPCR:
(NM_207624) ACE (S) N+322 to N+341 (50-AGGAGTTTGCAGAGGTCTGG-30
ACE (AS) N+525 to N+506 (50-GGAAGCAGACCTTGCCAGTG-30)
(NM_027286) ACE2 (S) N+917 to N+939 (50-AGGAGGAAGTTGATGGATAC
CTA-30)
ACE2 (AS) N+1191 to N+1170 (50-GGCTCAGTCAGCATAGAGT
TTG-30)
(NM_007525) Bax (S) N+179 to N+199 (50-TCATGAAGACAGGGGCCTTTT-30)
Bax (AS) N+364 to N+344 (50-CAATCATCCTCTGCAGCTCCA-30)
(NM_009743) Bcl-xL (S) N+493 to N+516 (50-TACCGGAGAGCGTTCAGTGAT
CTA-30)
Bcl-xL (AS) N+672 to N+649 (50-CTGCATCTCCTTGTCTACGC
TTTC-30)
(NM_007393) b-Actin (S) N+703 to N+723 (50-CGTGCGTGACATCAAAGAG
AA-30)
b-Actin (AS) N+839 to N+819 (50-GCTCGTTGCCAATAGTGAT
GA-30)
(NM_009931) Collagen IV(S) N+5826 to N+5846 (50-TAGGTGTCAGCAATTA
GGCAG-30)
Collagen IV(AS) N+6190 to N+6210(50-GCATTTCACACCTGA
GCACAC-30)
(NM_011333) MCP-1 (S) N+92 to N+110 (50-GTCCCTGTCATGCTTCTGG-30)
MCP-1 (AS) N+211 to N+191 (50-CATCTTGCTGGTGAATGAG
TA-30)
(NM_008871) PAI-1 (S) N+972 to N+989 (50-CTCATCAGACAATGGAAGA
GC-30)
PAI-1 (AS) N+1331 to N+1311 (50-CATCACTTGCCCCATGAAG
AG-30)
(NM_011577) TGF-b1 (S) N+1031 to N+1051 (50-CCAAACTAAGGCTCGCCA
GTC-30)
TGF-b1 (AS) N+1301 to N+1282 (50-GGCACTGCTTCCCGAAT
GTC-30)
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SUPPLEMENTARY MATERIAL
Figure A. Hematoxylin/eosin (H/E) staining ( 200 magnification)
of kidneys of male non-Tg (a), Agt-Tg (b), Cat-Tg (c) and Agt/Cat-Tg
(d) mice.
Figure B. Immunohistochemical staining ( 200 magnification)
of kidneys of male non-Tg (a), Agt-Tg (b), Cat-Tg (c) and Agt/Cat-Tg
(d) mice.
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